WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion
  • Wealthtech

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Executive Branch Updates
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • FDA Regulatory, Healthcare, and Consumer Products
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Elia Perez Villamarin
Associate
Corporate
San Francisco
evillamarin@wsgr.com

D415-947-2038

Download vCard
Open PDF

Elia Perez Villamarin is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where her practice focuses primarily on mergers and acquisitions. She advises both public and private clients in mergers, tender offers, asset acquisitions, stock purchases, and other strategic corporate transactions. Prior to joining the firm, Elia was an associate in the Madrid office of Clifford Chance (2016-2018) and a financial analyst in the Madrid office of Deloitte (2015-2016). She also worked for the directorate general for competition at the European Commission (Brussels).

Experience

Elia Perez Villamarin is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where her practice focuses primarily on mergers and acquisitions. She advises both public and private clients in mergers, tender offers, asset acquisitions, stock purchases, and other strategic corporate transactions. Prior to joining the firm, Elia was an associate in the Madrid office of Clifford Chance (2016-2018) and a financial analyst in the Madrid office of Deloitte (2015-2016). She also worked for the directorate general for competition at the European Commission (Brussels).

Education
  • LL.M., New York University School of Law, 2019
  • LL.M., Legal Practice, UNED, Madrid, 2016
  • LL.B., Universidad Carlos III de Madrid, 2014
  • B.B.A., Universidad Carlos III de Madrid, 2014
Admissions
  • State Bar of California
  • State Bar of New York
  • Bar Association of Madrid
Credentials
Education
  • LL.M., New York University School of Law, 2019
  • LL.M., Legal Practice, UNED, Madrid, 2016
  • LL.B., Universidad Carlos III de Madrid, 2014
  • B.B.A., Universidad Carlos III de Madrid, 2014
Admissions
  • State Bar of California
  • State Bar of New York
  • Bar Association of Madrid
Focus Areas
  • Corporate
  • Corporate Governance
  • Mergers & Acquisitions
  • Private Equity
Recent Insights
Client Highlights
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction. 
Learn More
Client Highlights
Wilson Sonsini Advises Sportsbox on Acquisition by Investor Group Led by Bryson DeChambeau
On April 7, 2026, a group of investors led by professional golfer Bryson DeChambeau announced its acquisition of Sportsbox AI, a leader in kinematic AI technology and 3D motion capture for coaching and training across mobile sports and fitness applications. Wilson Sonsini Goodrich & Rosati advised Sportsbox on the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.